Economic and Clinical Benefits of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV in Infants: A Cost-Effectiveness Analysis for Mexico

Background/Objectives: Respiratory syncytial virus (RSV) is a leading cause of respiratory infections in children. A novel RSVpreF vaccine for use among pregnant women for the prevention of RSV in infants is expected to be licensed in Mexico. Hence, the clinical and economic burden of RSV among infa...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	José Luis Huerta, Robyn Kendall, Luka Ivkovic, Carlos Molina, Amy W. Law, Diana Mendes
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	MDPI AG 2025-01-01
סדרה:	Vaccines
נושאים:	cost-effectiveness respiratory syncytial virus (RSV) RSVpreF vaccine maternal immunization Mexico economic evaluation
גישה מקוונת:	https://www.mdpi.com/2076-393X/13/1/77
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!